The European Commission has approved a label update for Cosentyx ( Secukinumab ).
Cosentyx is the first and only fully-human treatment that specifically inhibits interleukin-17A ( IL-17A ), in psoriatic arthritis ( PsA ).
IL-17A is produced by various cells from both the innate immune system (which can be triggered by mechanical stress) and the adaptive immune system.
The new label update includes dosing flexibility of up to 300 mg based on clinical response that provide clinicians with greater choice for their patients.
The label update also includes 24-week structural data with subcutaneous ( sc ) regimens demonstrating that Secukinumab inhibits progression of joint damage in psoriatic arthritis.
This label update is significant as psoriatic arthritis can lead to significant mobility loss and irreversible joint damage if sub-optimally-treated.
Psoriatic arthritis is a chronic, progressive and irreversible disease leading to pain, fatigue, as well as activity impairment and significant mobility loss due to structural damage.
The label update is based on Secukinumab sustained efficacy and consistent safety following up-titration to 300 mg in psoriatic arthritis.
The 24-week structural disease progression data are from FUTURE 5, the largest phase III study for a biologic conducted in psoriatic arthritis to date ( 996 patients ).
In this study, almost 90% of patients treated with Cosentyx 300 mg had no radiographic disease progression at 24 weeks. ( Xagena )
Source: Novartis, 2018